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a b s t r a c t
Over the past decade the introduction of drug-eluting stents (DESs) has revolutionised the treatment
of coronary artery disease. However, in recent years concern has arisen over the long-term safety and
efficacy of DESs due to the occurrence of late adverse clinical events such as stent thrombosis. With
this concern in mind, research and development is currently centred on increasing the long-term safety
and efficacy of DESs. The aim of this paper is to provide a thorough review of currently approved and
promising investigational DESs. With dozens of companies involved in the development of new and
innovative anti-restenotic agents, polymeric coatings and stent platforms, it is intended that this review
paper will provide a clear indication of how DESs are currently evolving and prove a valuable reference
tool for future research in this area.
© 2010 IPEM. Published by Elsevier Ltd. All rights reserved.
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1. Introduction
At present, coronary artery disease (CAD) is one of the lead-
ing causes of death and disability in the developed world.
According to the American Heart Association CAD was respon-
sible for approximately 445,687 deaths in the United States
in 2005, representing 20% of all deaths that year [1]. CAD is
caused by the development of atherosclerotic lesions within
one or more of the coronary arteries which deliver oxygen and
vital nutrients to the heart muscle. Several risk factors have
been identified that contribute to the progression of this dis-
ease and include smoking, hypertension, diabetes and increased
levels of cholesterol [1]. If the lumen becomes sufficiently nar-
rowed, blood flow to a portion of the heart is restricted, usually
resulting in angina pectoris. If untreated, vulnerable atheroscle-
rotic lesions can become unstable and rupture. This often
results in coronary occlusion and subsequent myocardial infarc-
tion.
Over the past two decades, percutaneous transluminal coro-
nary angioplasty (PTCA) with bare-metal stent (BMS) placement
has been utilised as a minimally invasive treatment for obstruc-
tive CAD. Typically, a BMS is a small, tubular, wire-mesh device
which is pre-loaded in a collapsed form onto a catheter bal-
loon, threaded to the narrowed section of the artery and
expanded within the vessel. Once expanded, the BMS acts as a
mechanical scaffold, reducing elastic recoil and maintaining ves-
sel patency post-treatment. For many patients who suffer from
CAD, treatment with a BMS will generally result in extremely
favourable initial clinical results. However, at follow-up (6–12
months), re-narrowing of the treated artery is commonly observed
in 20–30% of patients [2]. This re-narrowing of the treated
artery is due to in-stent restenosis (ISR) which is defined as
diameter stenosis of ≥50% in the stented area of the vessel
[3].
In recent years, DESs have been developed to address the prob-
lem of ISR. A DES typically consists of a BMS platform which has
been coated in a formulation of drugs and carrier materials. The
drugs commonly employed are known to interrupt the key cellular
and molecular processes associated with ISR. To date, clinical eval-
uation has overwhelmingly proven the superiority of DESs for the
reduction of ISR rates compared to BMSs, leading to the regulatory
approval of a number of DESs by both the European Union (EU)
Conformiteé Européenne (CE) and the US Food and Drug Admin-
istration (FDA). Despite the success of DESs in the treatment of
CAD, concern has arisen over the long-term safety and efficacy of
these devices due to cases of late adverse clinical events such as
stent thrombosis. With this concern in mind, research and devel-
opment in DES design is currently centred on increasing their
performance and long-term safety. Though only five distinct DESs
have received both CE and FDA approval for commercial sale in the
EU and the US, the number of DESs currently undergoing evalua-
tion is substantial. The aim of this paper is to provide a thorough
review of both currently approved and promising investigational
DESs.
In Section 2, a background on current DES technology is pro-
vided. In Section 3, the current CE and FDA approved DESs are
discussed in terms of their important design features and the clini-
cal trials which led to their approval. In Section 4, the long-term
safety and efficacy of DESs is discussed. In Section 5, a selec-
tion of promising investigational DESs are presented, while in
Section 6, conclusions are drawn and future prospects in the evo-
lution of DESs are discussed. With dozens of companies involved
in the innovation of DESs it is intended that this review paper
will provide a clear indication of how DESs are currently evolv-
ing and prove a valuable reference tool for future research in this
area.
2. Background
As mentioned in Section 1, DESs generally consist of up to three
components: (1) a stent, (2) a drug-delivery mechanism and (3) an
anti-restenotic drug or therapeutic agent. In this section, the types
and properties of each of these components is discussed.
2.1. The stent platform
Today, most stents employed by DESs are manufactured in
modular or slotted-tube configurations and are delivered by
balloon-dilation. The stent is crimped to a low-profile upon a
balloon-tipped catheter and introduced to the cardiovascular sys-
tem via the femoral or radial arteries. The stent must therefore
have a low crimped profile and must possess a high level of
flexibility to enable delivery through the tortuous cardiovascular
system. During expansion the stent should experience minimum
shortening and upon deployment should conform to the ves-
sel geometry without straightening the vessel unnaturally. The
stent should provide optimum vessel coverage and should pos-
sess high radial strength such that it undergoes minimal radial
recoil and achieves a final diameter consistent with that of the
host vessel upon unloading [4]. As the stent acts as a conduit for
drug-delivery it is also important that its geometrical configura-
tion facilitates homogeneous distribution of the drug within the
vessel [5].
Typically, stents are manufactured from biologically inert met-
als such as stainless steel. In recent years however, driven by
emerging correlations between strut thickness and rates of ISR,
metallic alloys such as cobalt–chromium have superseded steel as
the material of choice for stent design [6]. These metallic alloys
have been developed with increased levels of strength and X-ray
attenuation compared to stainless steel, allowing newer stents to
be designed with significantly thinner struts which do not impair
the resulting strength, corrosion resistance or radiopacity of the
device. Further development in stent design is currently centred
on the assessment of stronger metallic alloys, compound metals
and bioabsorbable materials.
2.2. The stent coating
Equally important as the actual drug or therapeutic agent that is
releasedbyaDES is themechanismbywhich thedrug is released. To
date, the most successful method of facilitating drug adhesion and
delivery from a stent has involved the use of permanent synthetic
polymer coating materials such as polyethylene-co-vinyl acetate
(PEVA), poly-n-butyl methacrylate (PBMA), and the tri-block co-
polymerpoly(styrene-b-isobutylene-b-styrene) (SIBS). Bycarefully
mixing anti-restenotic drugs with these materials, a drug-polymer
matrix may be formed and applied to the surface of the stent plat-
form. Upon deployment, drug-delivery is driven by diffusion from
the matrix and the rate of this diffusion is dictated by the type,
composition and number of polymers used in the drug–polymer
matrix.
In recent years these permanent polymers have been super-
seded by advanced biocompatible permanent polymers such
as phosphorylcholine (PC) and the co-polymer poly(vinylidene
fluoride-co-hexafluoropropylene) (PVDF-HFP). These advanced
polymers mimic the phospholipids on the outer surfaces of red
blood cells resulting in a stent platform that induces minimal
thrombus formation upon deployment and has minimal adverse
clinical effect on late healing of the vessel wall. Further devel-
opment in this area is currently centred on the assessment of
biocompatible and bioabsorbable polymer coating materials and
on the development of novel mechanisms of drug-release.
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Fig. 1. Cell-cycle and mechanism of action of sirolimus, zotarolimus, everolimus
and paclitaxel.
2.3. The anti-restenotic drug
During the deployment of aDES, anymechanical injury incurred
in the vessel leads to an immediate healing response in the arterial
wall. This healing response is initially characterised by the activa-
tion of platelets within the intima, leading to thrombus formation
and the recruitment of blood-borne monocytes, neutrophils and
lymphocytes. These cells produce mitogenic and chemotactic fac-
tors which trigger the activation of smooth muscle cells (SMCs)
which undergo unrestrained proliferation and migration toward
the intimal layer resulting in neointimal growth and ISR [7]. As
such, the ideal anti-restenotic agent should exhibit potent anti-
proliferative effects but preserve vascular healing. To date a vast
number of immunosuppressive and anti-proliferative agents have
been investigated for the prevention of ISR, however, only a small
number have shown real effectiveness in clinical evaluation.
Sirolimus, zotarolimus and everolimus, potent immunosup-
pressive agents, inhibit SMC proliferation in response to cytokine
and growth factor stimulation by binding to the cytosolic FK-
binding protein 12 (FKBP12). This prevents the activation of the
mammalian target of rapamycin (mTOR) and leads to interruption
of the cell-cycle in the G1-S phase. Paclitaxel, a strong anti-
proliferative agent, suppresses neointimal growth by binding with
and stabilising microtubules. The stability of these microtubules
inhibits their disassembly and renders themnon-functional, result-
ing in cell-cycle arrest in the G0–G1 and G2–M phases (Fig. 1) [7].
Development in this area is currently centred on the assessment of
further immunosuppressive and anti-proliferative agents as well
as the evaluation of numerous migration-inhibiting, enhanced-
healing and re-endothelialisation agents.
3. Current state of the art
Since 2002, five distinct DESs have received regulatory approval
fromtheboth theEUCEand theUSFDA: thefirst-generationCypher
sirolimus-eluting stent (SES) (Cordis, Johnson & Johnson, NJ, US),
the Taxus Express2 paclitaxel-eluting stent (PES) (Boston Scien-
tific, MS, US) and the Taxus Liberté PES (Boston Scientific), and
the second generation Endeavor zotarolimus-eluting stent (ZES)
(Medtronic Vascular, CA, US) and Xience-V everolimus-eluting
stent (EES) (Abbott Vascular, CA, US).
3.1. First-generation DESs
3.1.1. The Cypher SES
The Cypher SES consists of a Bx-Velocity BMS (Johnson & John-
son) coated in a formulation of sirolimus and two permanent
polymers, PEVA and PBMA. The Bx-Velocity BMS is a closed-cell,
Fig. 2. (a) Taxus Express2 PES and (b) Taxus Liberté PES.
slotted-tube stent manufactured from 316L stainless steel and
is comprised of a series of sinusoidal strut-segments joined by
N-shaped, flexible link-segments. The drug-polymer coating is
applied to the entire stent surface with a standard concentration
of 140g of sirolimus per cm2 of stent surface area and is designed
to release approximately 80% of the drug within 30 days of stent
deployment [8]. The Cypher SES is currently available in six lengths
from 8 to 33mm and four diameters from 2.25 to 3.5mm. The prin-
cipal safety and efficacy evidence for the Cypher SES was obtained
from five clinical trials: the First In Man (FIM) trial, the RAVEL trial,
and the SIRIUS trials (SIRIUS, E-SIRIUS and C-SIRIUS).
The FIM trial was a non-randomised trial involving 45 patients
that demonstrated minimal in-stent neointimal proliferation with
both fast- and slow-release SESs at 4 month follow-up [9]. The
RAVEL trial was a randomised trial involving 238 patients with rel-
atively low-risk lesions that demonstrated the superiority of the
Cypher SES over the Bx-Velocity BMS in terms of in-segment late
loss at 6 months [10]. The SIRIUS, C-SIRIUS and E-SIRIUS trials were
randomised trials involving a total of 1510patientswithmore com-
plex lesions than those enrolled in the RAVEL and FIM trials. The
superiority of the Cypher SES over the Bx-Velocity BMSwas further
demonstrated in these trials, with markedly lower rates of target-
lesion revascularisation and adverse clinical events observed in
patients treated with the Cypher SES [8,11,12]. The Cypher SES
became the first DES to receive both CE and FDA approval in April
2002 and April 2003, respectively.
3.1.2. The Taxus PESs
The Taxus Express2 PES consists of an Express BMS (Boston
Scientific) coated in a formulation of paclitaxel and a permanent
co-polymer, SIBS. The Express BMS is a closed-cell, slotted-tube
stent manufactured from 316L stainless steel and is comprised of a
series of sinusoidal strut-segments joined by straight articulations
to short, narrow strut-segments (Fig. 2). The drug-polymer coating
is applied to the entire stent surface in single layer with a standard
concentration of 100g of paclitaxel per cm2 of stent surface area.
The release of paclitaxel is bi-phasic with an early 48h burst fol-
lowed by a low-level release over the following 10 days [13]. The
Taxus Express2 PES is currently available in six lengths from 8 to
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33mm and four diameters from 2.5 to 3.5mm. The principal safety
and efficacy evidence for the Taxus Express2 PESwas obtained from
three clinical trials, the TAXUS I, II and IV trials.
The TAXUS I trial was a randomised trial involving 61 patients
which demonstrated zero binary in-stent restenosis with PESs at 6
months and minimal adverse clinical events compared to BMSs at
12 months [14]. The TAXUS II trial was a randomised trial involving
536 patients that demonstrated the superiority of both slow- and
fast-release PESs over BMSs in terms of stent volume obstructed
by neointimal proliferation at 6 months [15]. The TAXUS IV trial
was a randomised trial involving 1314 patients with more com-
plex lesions than those enrolled in the TAXUS I and II trials that
demonstrated the superiority of the Taxus Express2 PES over the
Express BMS in terms of in-stent late loss, binary in-stent resteno-
sis and target-lesion revascularisation at 9 months [13]. The Taxus
Express2 PES became the second DES to receive both CE and FDA
approval in May 2002 and March 2004, respectively.
Following FDA approval of the Taxus Express2 PES, the TAXUS
clinical trial program was succeeded by the TAXUS ATLAS trial,
designed to assess the drug-polymer coating (paclitaxel-SIBS)
employed by the Taxus Express2 PES upon a new BMS platform,
the Liberté stent (Boston Scientific). The Liberté stent is a closed-
cell, slotted-tube stent manufactured from 316L stainless steel
which has substantially thinner struts compared to the Express
stent (0.097 vs. 0.132mm) allowing for improved flexibility and
deliverability. The Liberté stent platform has also been specifically
designed with a dense strut configuration which ensures homo-
geneous distribution of paclitaxel within the vessel (Fig. 2). The
Taxus Liberté PES is currently available in seven lengths from 8 to
38mm and five diameters from 2.25 to 4mm. The principal safety
and efficacy evidence for the Taxus Liberté PES was obtained from
the TAXUS ATLAS trial.
The TAXUS ATLAS trial was a randomised trial involving 871
patients that compared the safety and efficacy of the Taxus Lib-
erté PES with an historic control arm of patients who were treated
with a Taxus Express2 PES in the TAXUS IV and V trials. Despite
a significantly higher incidence of complex lesions in the TAXUS
ATLAS patient population the Taxus Liberté PES was found to be
non-inferior to the Taxus Express2 PESwith similar rates of adverse
clinical events, in-stent late loss and target-vessel revascularisation
observed at 9 months [16]. The Taxus Liberté PES received CE and
FDA approval in September 2005 and October 2008, respectively.
3.2. Second-generation DESs
3.2.1. The Endeavor ZES
The Endeavor ZES consists of a Driver BMS (Medtronic Vascular)
coated in a formulationof zotarolimus and abiocompatible, perma-
nent PC co-polymer. The Driver BMS is an open-cell, modular stent
manufactured from MP35N cobalt–chromium and is comprised of
a series of alternating upper and lower crowns connected by axial
struts in a sinusoidal pattern. The use of MP35N cobalt–chromium
alloy allows for relatively thin struts (0.091mm) to be used com-
pared with first-generation DESs. The drug-polymer coating is
applied to the entire stent surface with a standard concentration
of 100g of zotarolimus per cm of stent length and is designed to
release approximately 95% of the total dose of zotarolimus within
15daysof stentplacement [17]. TheEndeavorZES is currently avail-
able in eight lengths from 8 to 30mm and three diameters from
2.5 to 3.5mm. The principal safety and efficacy evidence for the
Endeavor ZESwas obtained from four clinical trials, the ENDEAVOR
I–IV trials.
The ENDEAVOR I trial was a non-randomised trial involving 100
patients that demonstrated the safety and efficacy of the Endeavor
ZES with minimal binary in-stent restenosis observed at four and
12 months [17]. The ENDEAVOR II trial was a randomised trial
involving 1197 patients that demonstrated the superiority of the
Endeavor ZES over the Driver BMS with significantly lower rates
of binary in-stent restenosis and target-vessel revascularisation
observed at 8 and 9 months, respectively [18]. The ENDEAVOR III
(n=436) and ENDEAVOR IV (n=1548) trials were randomised tri-
als designed to demonstrate the non-inferiority of the Endeavor
ZES with the Cypher SES and Taxus Express2 PES, respectively. The
initial performance of the Endeavor ZES in these trials was dis-
appointing however, with markedly higher rates of target-lesion
revascularisation and significantly higher rates of in-stent late loss
observed with the Endeavor ZES at short-term follow-up in both
trials [19,20]. Results at longer-term follow-up have been more
reassuring however, with the absolute difference in target-lesion
revascularisation reduced to 1.6% at five years in the ENDEAVOR III
trial and 0.5% at three years in the ENDEAVOR IV trial [21,22]. The
Endeavor ZES received both CE and FDA approval in July 2005 and
February 2008, respectively.
3.2.2. The Xience-V EES
The Xience-V EES consists of a Multi-Link Vision BMS (Abbott
Vascular) coated in a formulation of everolimus, PBMA and a
permanent biocompatible co-polymer, PVDF-HFP. The Multi-Link
Vision BMS is a closed-cell, slotted-tube stent manufactured from
L605 cobalt–chromium alloy and consists of a series of corrugated,
zigzag strut-segments joined by single-turn link-segments. The use
of L605 cobalt–chromium alloy allows for relatively thin struts
(0.081mm) to be used compared with first-generation DESs. The
drug-polymer coating is applied to the entire stent surface with a
standard concentration of 100g of everolimus per cm2 of stent
surface area and is designed to release approximately 80% of the
total dose within 30 days of stent placement [23]. The Xience-V
EES is currently available in six lengths from 8 to 28mm and five
diameters from 2.5 to 4mm. The principal safety and efficacy evi-
dence for the Xience-V EES was obtained from four clinical trials:
the SPIRIT FIRST trial and the SPIRIT II–IV trials.
The SPIRIT FIRST trial was a randomised trial involving 60
patients that demonstrated the superiority of the Xience-V EES
over the Multi-Link BMS in terms of in-stent late loss and binary
in-stent restenosis at 6 months [23]. The SPIRIT II trial was a
randomised trial involving 300 patients that demonstrated the
superiority of the Xience-V EES over the Taxus Express2 PES in
terms of in-stent late loss at 6 months [24]. The SPIRIT III trial was
a randomised trial involving 1002 patients that demonstrated sig-
nificantly reduced in-segment late loss and non-inferior rates of
target-vessel failure in patients treated with a Xience-V EES com-
pared to the Taxus Express2 PES at 12 months [25]. The SPIRIT IV
trial is a randomised trial involving 3687 patients that has demon-
strated the superiority of the Xience-V EES over the Taxus Express2
PES in termsof target-lesion failure and target-vessel revascularisa-
tionat12months [26]. Interestingly, following threeyear follow-up
of the SPIRIT II and III trials, investigators observed an increase in
the absolute difference in target-vessel failure and adverse clin-
ical events in favour of the Xience-V EES [27,28]. The Xience-V
EES received CE and FDA approval in January 2006 and July 2008,
respectively.
3.3. Post-approval evaluation
Since obtaining CE and FDA approval, both first- and second-
generation DESs have been evaluated in dozens of clinical studies
to assess their safety and efficacy when deployed in a number
of patient and lesion sub-groups. These studies include evalu-
ations of DES delivery in small vessels, long lesions, diabetics,
chronic total occlusions (CTOs), bifurcatedvessels, sapheneousvein
grafts (SVGs), patients suffering from ISR, ST-elevated myocardial
ischemia, multi-vessel disease and by direct delivery [29–55]. The
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Table 1
Clinical trials of current CE- and FDA-approved DESs.
Study DES/BMS Aims Primary endpoint and outcome
Clinical trials of Cypher SES (Cordis, Johnson & Johnson)
C-SIRIUS Cypher SES To compare the efficacy of SES and BMS in long lesions Eight month minimum lumen diameter:
(n=100) [12] Bx-Velocity BMS SES: 2.46mm, BMS: 1.49mm (p<0.001)
DIABETES Cypher SES To compare the efficacy of SES and BMS in diabetics Nine month in-segment late lumen loss:
(n=160) [47] Bx-Velocity BMS SES: 0.06mm, BMS: 0.47mm (p<0.001)
E-SIRIUS Cypher SES To compare the efficacy of SES and BMS in long lesions Eight month minimum lumen diameter:
(n=352) [11] Bx-Velocity BMS SES: 2.22mm, BMS: 1.33mm (p<0.001)
FIM Cypher SES To assess the efficacy of slow- and fast-release (SR/FR)
SESs
Four month in-stent late loss:
(n=30) [9] SR SES: 0.09mm, FR SES: −0.02mm
MISSION Cypher SES To compare the efficacy of SES and BMS for STEMI Nine month in-segment late loss:
(n=310) [53] Multi-Link Vision BMS SES: 0.12mm, BMS: 0.68mm (p<0.001)
PRISON II Cypher SES To compare the efficacy of SES and BMS in CTOs Six month binary in-stent restenosis:
(n=200) [50] Bx-Velocity BMS SES: 7%, BMS: 36% (p<0.001)
RAVEL Cypher SES To compare the efficacy of SES and BMS Six month mean late loss
(n=238) [10] Bx-Velocity BMS SES: 0mm, BMS: 0.8mm (p<0.001)
RIBS II Cypher SES To compare the efficacy of SES and PTCA for ISR Nine month angiographic restenosis:
(n=150) [29] SES: 11%, PES: 39% (p<0.001)
RRISC Cypher SES To compare the efficacy of SES and BMS in SVG Six month in-stent late loss:
(n=75) [54] Bx-Velocity BMS SES: 0.38mm, BMS: 0.79mm (p=0.001)
SCANDSTENT Cypher SES To compare the efficacy of SES and BMS in complex
lesions
Six month minimum lumen diameter:
(n=322) [39] Bx-Velocity BMS SES: 2.48mm, BMS: 1.65mm (p<0.001)
SCORPIUS Cypher SES To compare the efficacy of SES and BMS in diabetics Eight month in-segment late loss:
(n=200) [31] Bx-Velocity BMS SES: 0.18mm, BMS: 0.74mm (p<0.0001)
SESAMI Cypher SES To compare the efficacy of SES and BMS for STEMI Twelve month binary in-segment restenosis:
(n=320) [43] Bx-Velocity BMS SES: 9.3%, BMS: 21.3% (p=0.032)
SES-SMART Cypher SES To compare the efficacy of SES and BMS in small
arteries
Eight month binary restenosis:
(n=257) [30] Bx-Velocity BMS SES: 9.8%, BMS: 53.1% (p<0.001)
SIRIUS Cypher SES To compare the efficacy of SES and BMS Nine month target-vessel failure rate:
(n=1,058) [8] Bx-Velocity BMS SES: 8.6%, BMS: 21.0% (p<0.001)
SIRIUS 2.25 Cypher SES To compare the efficacy of SES PTCA and BMS in small
arteries
Six month in-lesion binary restenosis:
(n=100) [35] Historic Control Arm SES: 16.9%, BMS: 45.9%, PTCA: 30.6%
STRATEGY Cypher SES To compare the efficacy of SES and BMS for STEMI Eight month rate of adverse clinical events:
(n=175) [52] Bx-Velocity BMS SES: 19%, BMS: 50% (p<0.001)
SVELTE Cypher SES To compare the efficacy of SES and BMS in small vessels Eight month target-lesion revascularisation:
(n=101) [42] Historic Control Arm SES: 0%, BMS: 13.2% (p<0.001)
TOSCA Cypher SES To assess the safety and efficacy of SES for CTOs Six month binary in-stent restenosis: 9.5%
(n=200) [36] Historic Control Arm Twelve month target-vessel failure rate: 10.9%
TYPHOON Cypher SES To compare the efficacy of SES and BMS for STEMI Twelve month target-vessel failure rate:
(n=712) [49] Bx-Velocity BMS SES: 7.3%, BMS: 14.3% (p=0.004)
Clinical trials of Taxus Express2 PES and Taxus Liberté PES (Boston Scientific)
SYNTAX Taxus Express2 PES To compare the efficacy of PES and bypass grafts Twelve month rate of adverse clinical events:
(n=1800) [48] PES: 17.8%, CABG: 12.4% (p=0.002)
TAXUS I Taxus NIRx PES To compare the efficacy of PES and BMS Twelve month rate late adverse clinical events:
(n=61) [14] NIR BMS PES: 3%, BMS: 10% (p=0.612)
TAXUS II Taxus NIRx PES To assess the efficacy of slow- and fast-release (SR/FR)
SESs and BMSs
Six month percent net volume obstruction:
(n=536) [15] NIR BMS SR PES: 6.9%, FR PES: 7.8%, BMS: 23.2%
TAXUS IV Taxus Express2 PES To compare the efficacy of PES and BMS Nine month target-vessel revascularisation:
(n=1314) [13] Express BMS PES: 4.7%, BMS 12.0% (p<0.001)
TAXUS V Taxus Express2 PES To compare the efficacy of PES and BMS Nine month target-vessel revascularisation:
(n=1,156) [130] Express BMS PES: 8.6%, BMS 15.7% (p<0.001)
TAXUS VI Taxus Express2 PES To compare the efficacy of PES and BMS Nine month target-vessel revascularisation:
(n=448) [131] Express BMS PES: 9.1%, BMS 19.4% (p<0.0027)
TAXUS ATLAS Taxus Liberté PES To compare the efficacy of Liberté PES and Express2 PES Nine month target-vessel revascularisation:
(n=871) [16] Historic Control Arm Liberté: 7.95%, Express2: 7.01% (p=0.05)
TAXUS ATLAS DS Taxus Liberté PES To compare direct-stenting (DS) and pre-dilation (PD)
Liberté PES
Nine month percentage diameter stenosis:
(n=247) [45] Historic Control Arm DS: 26.4%, PD: 29.1% (p=0.06)
TAXUS ATLAS LL Taxus Liberté PES To compare the efficacy of Liberté PES and Express2
PES in small vessels and long lesions
Nine month percentage diameter stenosis:
(n=411) [51] Historic Control Arm Liberté: 31.7%, Express2: 32.6% (p=0.69)
Clinical trials of Endeavor ZES (Medtronic Vascular)
ENDEAVOR I Endeavor ZES To assess the safety and efficacy of ZES Thirty day rate of adverse clinical events: 1%
(n=100) [17] Four month late lumen loss: 0.33mm
ENDEAVOR II Endeavor ZES To compare the efficacy of ZES and BMS Nine month target-vessel failure rate:
(n=1,197) [18] Driver BMS ZES: 7.9%, BMS: 15.1% (p<0.0001)
ENDEAVOR III Endeavor ZES To compare the efficacy of ZES and SES Eight month in-segment late loss:
(n=436) [19] Cypher SES ZES: 0.34mm, SES: 0.13mm (p<0.001)
ENDEAVOR IV Endeavor ZES To compare the efficacy of ZES and PES Nine month target-vessel failure rate:
(n=1,548) [20] Taxus Express2 PES ZES: 6.6%, PES: 7.1% (pnon-inferiority < 0.001)
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Table 1 (Continued)
Study DES/BMS Aims Primary endpoint and outcome
Clinical trials of Xience-V EES (Abbott Vascular)
SPIRIT FIRST Xience-V EES To compare the efficacy of EES and BMS Six month in-stent late loss:
(n=60) [23] Multi-Link Vision BMS EES: 0.10mm, BMS: 0.87mm (p<0.001)
SPIRIT II Xience-V EES To compare the efficacy of EES and PES Six month in-stent late loss:
(n=300) [24] Taxus Express2 PES EES: 0.11mm, PES: 0.36mm (p<0.0001)
SPIRIT III Xience-V EES To compare the efficacy of EES and PES Eight month in-stent late loss:
(n=1,002) [25] Taxus Express2 PES EES: 0.14mm, PES: 0.28mm (p=0.004)
SPIRIT IV Xience-V EES To compare the efficacy of EES and PES Twelve month target-lesion failure rate:
(n=3,687) [26] Taxus Express2 PES EES: 4.2%, PES: 6.8% (p=0.001)
Comparative trials of multiple DESs
COMPARE Xience-V EES To compare the efficacy of EES and PES in real world
setting
Twelve month rate of adverse clinical events:
(n=1,800) [38] Taxus Liberté PES EES: 6%, PES: 9% (p=0.02)
ISAR-DESIRE Cypher SES To compare the efficacy of SES, PES and PTCA for ISR Six month angiographic restenosis:
(n=300) [37] Taxus Express2 PES SES: 14.3%, PES: 21.7%, PTCA 44.6%
ISAR-DIABETES Cypher SES To compare the efficacy of SES and PES in diabetics Eight month in-segment late loss:
(n=250) [32] Taxus Express2 PES SES: 0.43mm, PES: 0.67mm (p=0.002)
ISAR-SMART-III Cypher SES To compare the efficacy of SES and PES in small vessels Eight month in-stent late loss:
(n=360) [41] Taxus Express2 PES SES: 0.25mm, PES: 0.56mm (p<0.001)
LONG-DES-II Cypher SES To compare the efficacy of SES and PES in small vessels Six month binary in-segment restenosis:
(n=500) [40] Taxus Express2 PES SES: 3.3%, PES: 14.6% (p<0.001)
REALITY Cypher SES To compare the efficacy of SES and PES Eight month binary in-lesion restenosis:
(n=1386) [44] Taxus Express2 PES SES: 9.6%, PES: 11.1% (p=0.31)
SIRTAX Cypher SES To compare the efficacy of SES and PES Nine month rate of adverse clinical events:
(n=1012) [55] Taxus Express2 PES SES: 6.2%, PES: 10.8% (p=0.009)
SORT-OUT-II Cypher SES To compare efficacy of SES and PES in a real world
setting
Nine month rate of adverse clinical events:
(n=2098) [33] Taxus Express2 PES SES: 9.3%, PES: 11.2% (p=0.16)
SORT-OUT-III Cypher SES To compare the efficacy of SES and ZES in a real world
setting
Nine month rate of adverse clinical events:
(n=1162) [46] Endeavor ZES SES: 3%, ZES: 6% (p=0.0002)
TAXI Cypher SES To compare the efficacy of SES and PES in a real world
setting
Six month rate of adverse clinical events:
(n=202) [34] Taxus Express2 PES SES: 6%, PES: 4% (p=0.8)
details and primary findings of these, and all previously mentioned
trials are presented in Table 1. These DESs have also been subject to
a number of physician-driven registries to assess their relative and
real-world performance [56–64]. The details and primary findings
of these registries are presented in Table 2.
4. Long-term DES safety
Following the strong performance of the first-generation DESs
in clinical evaluation, these devices were widely adopted by inter-
ventional cardiologists with up to 90% of stent procedures carried
Table 2
Registries of current CE- and FDA-approved DESs.
Registry DES Aim Outcome
RESEARCH (n=958) [61] Cypher SES
Conventional BMS
To compare the efficacy of the Cypher SES
and BMS in routine clinical practice
Twelve month rate of adverse clinical events: SES:
9.7%, BMS: 14.8% (p=0.008), 12 month
target-vessel revascularisation: SES: 3.7%, BMS:
10.9% (p<0.001)
E-CYPHER (n=15157) [64] Cypher SES To assess the Cypher SES in routine clinical
practice and to identify predictors of
adverse clinical events
Twelve month rate of adverse clinical events: 5.8%,
12 month target-vessel revascularisation: 3.07%,
12 month incidence of stent thrombosis: 0.87%
US-PMS (n=2067) [59] Cypher SES To compare the efficacy of SES in on-label
(ON-L) and off-label (OFF-L) patient
populations
Twelve month rate of adverse clinical events:
ON-L: 4.7%, OFF-L: 9.2% (p<0.001) 12 month
target-vessel revascularisation: ON-L: 2.5%, OFF-L:
6.2% (p<0.001)
WISDOM (n=778) [56] Taxus Express2 PES To assess the efficacy of the Taxus Express2
PES in routine clinical practice
Twelve month rate of adverse clinical events: 5.2%,
12 month target-vessel revascularisation: 2.0%, 12
month incidence of stent thrombosis: 0.6%
ARRIVE 1 & 2 (n=7601) [60] Taxus Express2 PES To compare the efficacy of PES in simple
use (SU) and expanded use (EU) patient
populations
Two year target-vessel revascularisation: SU: 5.4%,
EU: 9.2% (p<0.001), two year rate of stent
thrombosis: SU: 1.4%, EU: 3.3% (p<0.001)
T-SEARCH (n=576) [62] Taxus Express2 PES
Historic Control Arm
To compare the efficacy of the Taxus
Express2 PES and the Cypher SES in routine
clinical practice
Twelve month rate of adverse clinical events: SES:
10.5%, PES: 13.9% (p=0.4), 12 month target-vessel
revascularisation: SES: 3.7%, PES: 5.4% (p<0.3)
TAXUS OLYMPIA (n=529) [57] Taxus Liberté To assess the efficacy of the Taxus Liberté
PES in routine clinical practice
Twelve month rate of adverse clinical events: 3.7%,
12 month target-vessel revascularisation: 2.3%, 12
month incidence of stent thrombosis: 1.7%
E-FIVE (n=8300) [58] Endeavor ZES To assess the efficacy of the Endeavor ZES
in routine clinical practice
Twelve month rate of adverse clinical events: 7.5%,
12 month target-vessel revascularisation: 4.5%, 12
month incidence of stent thrombosis: 1.1%
X-SEARCH (n=649) [63] Xience-V EES 3
Historical Control Arms
To compare the efficacy of the Xience-V
EES with SES, PES and BMS in routine
clinical practice
Twelve month rate of adverse clinical events: EES:
9.2%, SES: 7.3%, PES: 9.9%, BMS: 10.4%, 12 month
target-vessel revascularisation: EES: 3.1%, SES:
2.2%, PES: 4.3%, BMS: 5.8%
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Fig. 3. Scanning electronmicrographs of 14-day endothelial coverage of Cypher SES, Taxus Liberté PES, Endeavor ZES, Xience-V EES andMulti-Link BMS in rabbit iliac arteries.
out in the US involving DES placement by late 2005 [65]. Over
the following two years, however, major concerns arose over the
long-term safety of DESs when a number of clinical and observa-
tional studies reported significantly increased risk of mortality in
patients treated with DESs compared to BMSs beyond 12 months
[66–69]. Prompted by these results, a number of large-scale, meta-
analyses were undertaken to assess both the short- and long-term
safety of DESs relative to BMSs [70–72]. Reassuringly, no increased
risk of mortality was observed between patients treated with DESs
and BMS with similar rates of death and myocardial infarction
reported for DESs in each of these studies. Furthermore, in a recent
meta-analysis of long-term follow-up (1–4 years) from over 22
randomised clinical trials and 34 observational studies, patients
treated with DESs were associated with lower rates of death and
myocardial infarction and repeat revascularisations compared to
patients treated with BMSs [73].
Today, the primary concern with long-term DES safety is stent
thrombosis, a potentially fatal adverse event that often leads to
myocardial infarction and/or death. In the debate that followed
the initial concerns over the long-term safety of DESs it emerged
that restrictive and non-uniform definitions of stent thrombosis
had been utilised during the initial clinical evaluation of the first-
generationDESs. TheAcademic Research Consortium subsequently
recommended standardised definitions of stent thrombosis and in
2007 these definitions were adopted in a pooled analysis of the
long-term follow-up from eight clinical trials involving both the
Cypher SES and the Taxus Express2 PES. Though similar rates of
early (less than 1 month) and late (1–12 months) stent thrombo-
sis were observed between DESs and BMSs in this analysis, higher
rates of very-late (greater than 12 months) stent thrombosis were
reported with DESs [74]. Evaluation of the long-term follow-up of
clinical trials and registries has since supported this observation
[75–77].
Although the exact cause of stent thrombosis is not yet fully
understoodanumber of patient, lesion, andprocedural factors have
been associated with an increased risk of stent thrombosis. These
include, increasing age, diabetes mellitus, renal failure, increasing
stent and/or lesion length, decreasing stent and/or vessel diam-
eter, treatment of bifurcation, treatment of CTO, treatment of ISR,
stent under-expansion andpremature discontinuation of dual anti-
platelet therapy [78,79]. Of note, recent studies have identified
delayed healing and incomplete endothelial strut coverage as a pri-
mary risk factor for stent thrombosis [80–83]. It has been shown
that the non-erodible polymer coatings employed by DESs (par-
ticularly the first-generation Cypher SES and Taxus Express2 PES)
impair stent strut endothelialisation and may induce late hyper-
sensitivity reactions and subsequent stent thrombosis (Fig. 3) [84].
As a result of these findings, research in this area is currently cen-
tred on the development and evaluation of improved DESs which
maintain the impressive clinical benefits observed with currently
approveddeviceswhile eradicating long-termsafety concerns such
as stent thrombosis.
5. Future of DESs
In this section a number of promising investigational DESs are
presented and discussed. These DESs are categorised as either per-
manent DESs or bioabsorbable DESs and are sub-categorised by
the type of polymer coatingwhich they employ: permanent, bioab-
sorbable or polymer free. Each of theseDESs is discussed in terms of
its novel design features and its performance in clinical evaluation
to date. A brief summary of these investigational DESs and the cur-
rent CE and FDA approved devices discussed in previous sections is
presented in Table 3.
5.1. Permanent DESs
5.1.1. Permanent polymer-coated DESs
5.1.1.1. The Taxus Element PES and Promus Element EES. The Taxus
Element PES (Boston Scientific) and Promus Element EES (Boston
Scientific) consist of a novel platinum–chromium stent coated in
the same drug-polymer formulation as the Liberté PES (paclitaxel-
SIBS) and the Xience-V EES (everolimus-PVDF-HFP), respectively.
Thematerial properties of platinum–chromiumprovide theseDESs
with increased radial strength and fracture resistance allowing for
thinner stent struts (0.081mm) compared to both stainless steel
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Table 3
Current CE-/FDA-approved and promising investigational DESs.
Drug DES Stent material/coating material Principal trials Approval
Sirolimus Cypher (Johnson & Johnson) Stainless Steel (316L)/Permanent Polymer (PEVA-PBMA) FIM, RAVEL, SIRIUS,
E-SIRIUS, C-SIRIUS
CE/FDA
Nevo (Johnson & Johnson) Cobalt–Chromium (N/A)/Bioabsorbable Polymer (PLGA) NEVO RES, NEVO RES II –
Yukon Choice (Translumina) Stainless Steel (316L)/None ISAR-TEST, ISAR-TEST 3,
ISAR-TEST 4, ISAR-PEACE
CE
Supralimus (Sahajanand Medical) Stainless Steel (316L)/Bioabsorbable Polymer
(PLLA–PVP–PLGA)
SERIES I, SERIES III RUN IN –
BTI (Bioabsorbable Therapeutic Inc.) Bioabsorbable Polymer (PA & Salicylic Acid)/Bioabsorbable
Polymer (Salicylic Acid)
WHISPER –
Genous (OrbusNeich) Stainless Steel (316L)/Combo EPC Capture Antibodies,
SynBiosys Polymer and Sirolimus
REMEDEE –
ReZolve SES (REVA Medical) Tyrosine-derived ReZorb Bioabsorbable Polymer – –
Paclitaxel Taxus Express2 (Boston Scientific) Stainless Steel (316L)/Permanent Polymer (SIBS) TAXUS I-IV CE/FDA
Taxus Liberté (Boston Scientific) Stainless Steel (316L)/Permanent Polymer (SIBS) TAXUS IV-VI
TAXUS ATLAS
CE/FDA
Taxus Element (Boston Scientific) Platinum–Chromium (N/A)/Permanent Polymer (SIBS) PERSEUS CE
Infinnium (Sahajanand Medical) Stainless Steel (316L)/Bioabsorbable Polymer
(PLLA–PVP–PLGA)
SIMPLE I–II CE
Zotarolimus Endeavor (Medtronic Vascular) Cobalt–Chromium (MP35N)/Permanent Polymer (PC) ENDEAVOR I–IV CE/FDA
Endeavor Resolute (Medtronic Vascular) Cobalt–Chromium (MP35N)/Bioabsorbable Polymer
(BioLinx: C19-PVP-C10)
RESOLUTE, RESOLUTE-AC
RESOLUTE-US
CE
Everolimus Xience-V (Abbott Vascular) Cobalt–Chromium (L605)/Permanent Polymer (PVDF-HFP) SPIRIT I-IV CE/FDA
Xience Prime (Abbott Vascular) Cobalt–Chromium (L605)/Permanent Polymer (SIBS) SPIRIT PRIME CE
Promus Element (Boston Scientific) Platinum-Chromium (N/A)/Permanent Polymer (SIBS) PLATINUM CE
BVS (Abbott Vascular) Bioabsorbable Polymer (PLLA)/Bioabsorbable Polymer
(PDLLA)
ABSORB, ABSORB EXTEND –
Biolimus BioMatrix (Biosensors) Stainless Steel (316L)/Bioabsorbable Polymer (PLLA) STEALTH I, LEADERS CE
BioFreedom (Biosensors) Stainless Steel (316L)/None BIOFREEDOM FIM –
Nobori (Terumo) Stainless Steel (316L)/Bioabsorbable Polymer (PLLA) NOBORI I, NOBORI II CE
Tacrolimus Janus (Sorin Biomedical) Stainless Steel (316L)/Carbofilm (pyrolytic carbon) JUPITER I, JUPITER II CE
Novolimus DESyne (Elixir Biomedical) Cobalt–Chromium (N/A)/Permanent Polymer (N/A) EXCELLA, EXCELLA II –
and cobalt–chromium DESs. The density of platinum–chromium
is also greater than that of either 316L stainless steel or cobalt-
chromium which ensures improved visibility of the thinner struts,
while the continuous cell geometry also ensures homogeneous
drug-delivery along the length of these DESs.
The Taxus Element PES and Promus Element PES are currently
undergoing clinical evaluation in the PERSEUS and PLATINUM tri-
als, respectively. The PLATINUM clinical trial program completed
enrolment of 1532 patients in September 2009 and is designed to
compare the safety and efficacy of the Promus Element EES against
the Xience-V EES for the treatment of up to two de novo lesions.
Two parallel sub-trials are also planned to assess the performance
of the Promus Element EES in both small vessels and long lesions.
The Promus Element EES received CE approval in October 2009.
The PERSEUS clinical trial program involves two parallel stud-
ies, a workhorse trial and a small vessel trial. The PERSEUS
Workhorse trial is a randomised trial involving 1262 patients that
has demonstrated the non-inferiority of the Taxus Element PES
against the Taxus Express2 PES in terms of target-lesion failure at
12 months (Element: 5.6% vs. Express2: 6.1%, p=0.78) and percent-
age diameter stenosis at 9 months (Element: 26.1±17.7mm vs.
Express2: 26.3±17.4, p=0.92). No differences in rates of adverse
clinical events, mortality, revascularisation or stent thrombosis
were observed between stent groups at 12 months [85]. The
PERSEUS Small Vessel trial is a single-arm trial involving 224
patients with lesion diameter 2.25–2.75mm which has demon-
strated the superiority of the Taxus Element PES against an
historical control arm of Express BMSs in terms of in-stent late
loss at 9 months (PES: 0.38±0.51mm vs. BMS: 0.80±0.53mm,
p<0.001) and target-lesion failure at 12months (PES: 6.6% vs. BMS:
20.5%, p=0.01). Similar rates of mortality and stent thrombosis
were also observed between stent groups at 12 month follow-
up [86]. The Taxus Element PES received CE approval in May
2010.
5.1.1.2. The Endeavor Resolute ZES. The Endeavor Resolute ZES
(Medtronic Vascular) consists of a Driver BMS coated in a for-
mulation of zotarolimus and a proprietary polymer referred to
as Biolinx. Compared with the PC polymer coating employed by
the Endeavor ZES the BioLinx polymer, which consists of a unique
blend of a hydrophilic C19 polymer, polyvinyl pyrrolidone (PVP)
and a hydrophobic C10 polymer, provides the Endeavor Resolute
with improved biocompatibility, increased coating durability and
extended drug elution. The Endeavor Resolute ZES is currently
undergoing clinical evaluation in the RESOLUTE and RESOLUTE AC
trials.
The RESOLUTE trial is a non-randomised trial involving 139
patients which has demonstrated the safety and efficacy of the
Endeavor Resolute ZES in terms of in-stent late loss at 9 months
(0.22±0.27mm) [87]. The long-term safety and efficacy of the
Endeavor Resolute ZES has also been demonstrated with low
rates of adverse clinical events (11.6%), target-lesion revasculari-
sation (1.6%) and stent thrombosis (0.0%) reported at three year
follow-up in theRESOLUTE trial [88]. TheRESOLUTEAC trial is a ran-
domised, all-comers trial involving approximately 2300 patients
that has demonstrated the non-inferiority of the Endeavor Resolute
ZES against the Xience-V EES for predominantly off-label indica-
tions in terms of target-lesion failure at 12 months (ZES: 8.2% vs.
EES: 8.3%, p=0.94) and in-stent diameter stenosis at 13 months
(ZES: 21.6±14.4mmvs. EES: 19.7±14.6, pnon-inferiorirty = 0.04) [89].
Long-term follow-up of these trials is planned, while further evalu-
ation of the Endeavor Resolute ZES is scheduled with enrolment of
the RESOLUTE US trial currently underway. The Endeavor Resolute
ZES received CE approval in October 2007.
5.1.1.3. The Xience Prime EES. The Xience Prime EES (Abbot Vas-
cular) consists of an L605 cobalt–chromium stent coated in the
same drug-polymer formulation as the Xience-V EES. This stent
platform is designed to allow for high flexibility and deliverabil-
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ity in more challenging lesions and is currently undergoing clinical
evaluation in the SPIRIT PRIME trial, a non-randomised trial involv-
ing 500 patients that has been designed to evaluate the safety
and efficacy of the Xience Prime EES in terms of adverse clini-
cal events at 12 months. Enrolment in XIENCE PRIME began in
June 2009 following the announcement that it had received CE
approval.
5.1.1.4. The Elixir DESyne Novolimus-Eluting Stent (NES). The Elixir
DESyne NES (Elixir Medical, CA, US) consists of a thin strut
(0.081mm) cobalt–chromium stent which is coated in a formu-
lation of novolimus and PMBA. Novolimus, a sirolimus analogue
with similar immunosuppressive properties, inhibits the activation
of mTOR resulting in cell-cycle interruption in the G1-S phase. The
drug-polymer coating is applied to the entire stent surface with a
standard concentration of 85g of novolimus per cm2 of stent sur-
face area and is designed to ensure a sustained release of novolimus
over a four to six week period.
The Elixir DESyne NES is currently undergoing clinical evalu-
ation in the EXCELLA and EXCELLA II trials. The EXCELLA trial is
a non-randomised trial involving 15 patients that demonstrated
the safety and efficacy of the Elixir DESyne NES with low rates of
in-stent late loss observed at four (0.15±0.29mm) and 8 months
(0.31±0.25mm) [90]. The long-term safety and efficacy of the
Elixir DESyne NES has also been demonstrated in this small patient
population with only one adverse clinical event reported at two
year follow-up in the EXCELLA trial [91]. The EXCELLA II trial is
a randomised trial involving 210 patients that demonstrated the
superiority of the Elixir DESyneNES over the Endeavor ZES in terms
of in-stent late loss at 9 months (NES: 0.11±0.32mm vs. ZES:
0.63±0.42mm, p<0.001). Additionally, there were no significant
differences between stent groups in terms of a composite endpoint
of cardiac death, target-vessel myocardial infarction and clinically
indicated target-lesion revascularisation at 9 months (NES: 2.9%
vs. ZES: 5.6%, p=0.45) [92]. As the strut thickness and polymer
employed by both devices are similar, this superiority has been
attributed to the slower release kinetics of the drug-polymer coat-
ing employed by Elixir DESyne NES.
5.1.2. Bioabsorbable polymer-coated DESs
5.1.2.1. The Nevo SES. The Nevo SES (Johnson & Johnson) consists
of a cobalt–chromium, open-cell stent which is dotted with multi-
ple laser-cut holes within its struts that serve as micro-reservoirs
which are loaded with a formulation of sirolimus and a bioab-
sorbablepolymer calledpoly-d,l-lactide-co-glycolide (PLGA). PLGA
is formed by co-polymerisation of monomers of d,l-lactic acid and
glycolic acid and, in the body, is degraded by hydrolysis of ester
links with by-products easily metabolised via the Krebs cycle. The
Nevo SES is designed to ensure a similar drug-release profile to the
Cypher SESwith drug-delivery from themicro-reservoirs driven by
a combination of diffusion and bulk-erosion of the drug-polymer
formulation.
Reservoir-based drug-deliverywas initially introducedwith the
Costar PES (Conor Medsystems Inc., CA, US). Though the Costar
PES performed well in early clinical evaluation it was associated
with significantly increased rates of target-vessel revascularisation
(Costar: 8.1% vs. Express2: 4.3%, p=0.002) at 8 months follow-up
of the COSTAR-II trial, a randomised trial involving 1700 patients,
in which the safety and efficacy of the device was compared to
that of the Taxus Express2 PES [93]. Although the precise cause
of this failure was unclear, investigators singled out the complex
patient/lesion population enrolled in the trial and the poor imme-
diate drug-release rate of the Costar PES as possible causes. Despite
the apparent failure of the Costar PES, the Nevo SES has enjoyed
promising results in early clinical evaluation in the NEVO-RES-I
study.
The NEVO-RES-I study is a randomised trial involving 394
patients that has demonstrated the superiority of the Nevo SES
over the Taxus Liberté PES in terms of in-stent late lumen loss at
6 months (SES: 0.13±0.31mm vs. PES: 0.36±0.46mm, p<0.001)
with all other angiographic and clinical endpoints either statisti-
cally ornumerically favouring theNevoSES [94]. Further evaluation
of the Nevo SES is currently scheduledwith the NEVO-II andNEVO-
III trials. The NEVO II trial is a randomised trial involving 2500
patients designed to compare the safety and efficacy of the Nevo
SES with the Xience-V EES. The NEVO III trial is a non-randomised
trial involving 1300 patients designed to compare the safety and
efficacy of the Nevo SES with the Cypher SES.
5.1.2.2. The Supralimus SES and Infinnium PES. The Supralimus SES
(Sahajanand Medical Technologies, Gujrat, India) consists of a
316L stainless steelMatrixBMS (SahajanandMedical Technologies)
coated in a formulation of sirolimus and three bioabsorbable poly-
mers, poly l-lactide (PLLA), polyvinyl-pyrrolidone (PVP) and PLGA.
The drug-polymer coating is applied to the stent platform in two
layers: a base layer consisting of 140g sirolimus per cm2 stent
surface area which is incorporated in a PLLA–PLGA–PVP matrix
and an outer polymer-only layer of PVP which prevents prema-
ture drug-release and is completely absorbed within two hours of
stent deployment. Following absorption of this outer layer, an ini-
tial burst-phase releases 50% of the entire dose of sirolimus within
the first 7 days, with the remaining drug released over approxi-
mately 41 days. The Supralimus SES is currently undergoing clinical
evaluation in the SERIES I and SERIES III RUN IN trials.
The SERIES I trial is a non-randomised trial involving 126
patients which has demonstrated the safety and efficacy of the
Supralimuswith low rates of in-stent late loss (0.09±0.37mm)and
binary in-stent restenosis (0%) reported at 6 months. Furthermore,
low rates of adverse clinical eventswere reported at both 9 (6%) and
30month (7%) follow-up [95]. Further evaluation of the Supralimus
SES is currently underway in the SERIES III trial, a randomised trial
involving 360 patients designed to compare the safety and efficacy
of the Supralimus SES with the Xience-V EES.
The Infinnium PES (Sahajanand Medical Technologies) is very
similar to the Supralimus SES in that it consists of the same
316L stainless steel Matrix BMS and bioabsorbable polymer
matrix (PLLA-PVP-PLGA) but incorporates paclitaxel as opposed
to sirolimus. The drug-release profile of the Infinnium PES is
much the same as that of the Supralimus SES with complete
drug-delivery taking approximately 48 days. The Infinnium PES is
currently undergoing clinical evaluation in the SIMPLE II trial, a
non-randomised registry involving 103 patients that has demon-
strated the safety andefficacyof the InfinniumPESwith low rates of
adverse clinical events observed at 1 (2.9%), 6 (3.9%) and 9 months
(6.8%). Furthermore, 6 month angiographic follow-up revealed low
rates of in-segment late loss (0.18±0.45mm) andbinary restenosis
(8.3%) [96]. The drug-polymer formulations employed by both the
Supralimus SES and the Infinnium PES have recently been incorpo-
rated on the L605 cobalt–chromium Corronium BMS (Sahajanand
Medical Technologies) andclinical evaluationof theseDESs is antic-
ipated
5.1.2.3. The BioMatrix and Nobori biolimus-eluting stents (BESs).
The BioMatrix BES (Biosensor Interventional, Morges, Switzerland)
consists of a 316L stainless steel S-Stent BMS (Biosensor Interven-
tional) coated in a formulation of biolimus and a bioabsorbable
polymer, PLLA. Biolimus is a sirolimus analogue that possesses
similar anti-inflammatory properties whilst exhibiting a higher
lipophilic and hydrophobic profile. As such, biolimus is more
rapidly absorbed by the vessel wall where it induces cell cycle
arrest in the G0 phase. The drug is mixed in a formulation with
PLLA polymer and applied to the abluminal surface of the S-Stent
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with a concentrationof 156gper cmof stent length.Upondeploy-
ment, the drug-polymer formulation is designed to release the drug
in a two-phase process with an initial burst release followed by the
simultaneous process of sustaineddrug release andpolymer degra-
dation. Both the drug and polymer are fully absorbed within 6–9
months.
The principal safety and efficacy evidence for the BioMatrix BES
was obtained from the STEALTH I and LEADERS trials. The STEALTH
I trial was a randomised trial involving 120 patients that demon-
strated the superiority of the BioMatrix BES over the S-Stent BMS
in terms of in-lesion late loss at 6 months (BES: 0.14±0.45mm
vs. BMS: 0.40±0.41mm, p=0.004). The secondary study endpoint
of event-free survival at 6 months was similar in both groups
(BES: 96.3% vs. BMS: 97.5%, p=0.82) and no significant differences
were observed in rates of target-lesion revascularisation due to low
binary in-stent restenosis rates in both stent groups (BES: 3.9% vs.
BMS: 7.7%, p=0.4) [97]. The LEADERS trial is a randomised trial
involving 1707 patients that has demonstrated the non-inferiority
of the BioMatrix BES against the Cypher SES in terms a composite
endpoint of death, myocardial infarction and target-vessel revas-
cularisation at 9 months (BES: 9% vs. SES: 11%, p=0.39) [98]. The
long-term safety and efficacy of the BioMatrix BES has also been
demonstrated in this patient population with non-inferior rates of
this composite endpoint reported at both one (BES: 10.7% vs. SES:
12.1%, p=0.37) and two years (BES: 13.0% vs. SES: 15.4%, p=0.18)
[99]. The BioMatrix BES received CE approval in April 2008.
In May 2007, Terumo Corporation (Leuven, Belgium) agreed
to license the BioMatrix BES, re-branding it as the Nobori BES,
and began enrolment in the NOBORI I trials. The first phase of
the NOBORI I trial was a randomised trial involving 120 patients
that demonstrated the non-inferiority of the Nobori BES against
the Taxus Express2 PES in terms of in-stent late loss at 9 months
(BES: 0.15±0.27mm vs. PES: 0.32±0.33mm, p=0.006) [100]. The
second phase of the NOBORI I trial was a randomised trial involv-
ing 243 patients that demonstrated the superiority of the Nobori
BES over the Taxus Liberté PES in terms of in-stent late loss (BES:
0.11±0.30mm vs. PES: 0.32±0.50mm, p=0.001) and binary in-
stent restenosis (BES: 0.7% vs. PES: 6.2%, p=0.02) at 9months [101].
Further evaluation of the Nobori BES is currently underway in the
NOBORI II trial, which began enrolment in March 2009.
5.1.3. Polymer-free DESs
5.1.3.1. The Yukon SES. The Yukon SES (Translumina, Hechingen,
Germany) consists of a 316L stainless steel stent platform with a
microporous surface finish that facilitates direct drug adhesion and
polymer-free drug-delivery. The microporous stent is coated in a
reported 2% solution of sirolimus and is designed to deliver the
entire dose within three weeks of stent deployment. The princi-
pal safety and efficacy evidence for the Yukon SES is derived from
the ISAR-TEST trial, a randomised trial involving 450 patients that
has demonstrated the non-inferiority of a polymer-free Yukon SES
against the Taxus Express2 PES in terms of in-stent late lumen loss
at 9months (SES: 0.48±0.61mmvs. PES: 0.48±0.58mm, p=0.98).
No significant differences between stent groups were observed
in rates of binary in-stent restenosis (SES: 12.6% vs. PES: 11.6%,
p=0.78) and target-lesion revascularisation (SES: 9.3%vs. PES: 9.3%,
p=1.0) at 9 months [102]. The polymer-free Yukon SES received CE
approval in 2003.
Following the results of the ISAR-TEST trial, the safety and effi-
cacy of Yukon SESs were further evaluated in the ISAR-TEST-3 and
ISAR-TEST-4 trials. The ISAR-TEST-3 trial was a randomised trial
that compared the safety and efficacy of a polymer-free Yukon SES,
a bioabsorbable (shellac resin-based) polymer-coated Yukon SES
and the Cypher SES. At 12 months, similar rates of adverse clinical
events were reported for each DES. However, while the bioab-
sorbable polymer-coated Yukon SES was found to be non-inferior
to theCypher SES, thepolymer-freeYukonSESwas found tobe infe-
rior in terms of mean late loss at 6 months (Yukon: 0.47±0.56mm
vs. Cypher: 0.23±0.46, pnon-inferiority = 0.94) [103]. These observa-
tions were later supported by results from the ISAR-TEST-4 trial,
a randomised trial involving 2603 patients that demonstrated
the non-inferiority of a bioabsorbable polymer-coated Yukon SES
against a control arm of patients treated with Cypher SESs or
Xience-V EESs in terms of a composite of cardiac death, myocar-
dial infarction and target-vessel revascularisation (Yukon: 13.8%
vs. Endeavor/Xience-V: 14.4%, p=0.66) at 12 months [104]. Fur-
ther evaluation of the bioabsorbable polymer-coated Yukon SES is
currently underway in the ISAR-TEST-5 trial.
5.1.3.2. The BioFreedom BES. The BioFreedomBES (Biosensor Inter-
ventional) is similar in its design to the Yukon SES in that it utilises
microporous surface finishing to facilitate polymer-free drug adhe-
sion and delivery. The BioFreedom BES consists of a microporous
316L stainless steel S-Stentwhich is coated on its abluminal surface
with biolimus. The safety and efficacy of the BioFreedomBES is cur-
rently under evaluation in theBIOFREEDOMFIMtrial, a randomised
trial involving 180 patients which is designed to assess the safety
and efficacy of lowdose (78g of biolimus per cm stent length) and
standard dose (156g of biolimus per cmstent length) BioFreedom
BESs relative to the Taxus Liberté PES. Results from the first cohort
of this trial have demonstrated the non-inferiority of the BioFree-
dom BES in terms of in-stent late loss (Low Dose BES: 0.08mm
vs. Standard Dose BES: 0.12mm vs. PES: 0.37mm, p<0.0001 and
p=0.002, respectively) at 4 months [105]. Evaluation of a second
cohort of patients enrolled in the BIOFREEDOMFIM trial is ongoing.
5.1.3.3. The Janus Tacrolimus-Eluting Stent (TES). The Janus TES
(Sorin Biomedica Cardio, Italy) consists of a Carbostent BMS (Sorin
Biomedica Cardio) which incorporates multiple micro-reservoirs
cut into its abluminal side that are loaded with tacrolimus, a
non-cytotoxic T-cell inhibitor, which inhibits smooth muscle cell
proliferation in the G0 phase (Fig. 4). The drug is embedded in
these reservoirs, which are designed to ensure abluminal-side
drug-delivery only, with a standard concentration of 230g of
tacrolimus per cm2 of stent surface area. The entire stent surface
is coated with a high density ultrathin film of thrombo-resistant
pyrolytic carbon (Carbofilm) which is designed to improve over-
all biocompatibility of the device. The principal safety and efficacy
evidence for the Janus TES was obtained from the JUPITER II trial,
a randomised trial involving 332 patients that demonstrated the
non-inferiority of the Janus TES against a carbofilm-coated Car-
bostent BMS in terms of in-stent late loss at 6 months (TES:
0.65±0.47mm vs. BMS: 0.66±0.53mm, p=non-significant) and
rates of adverse clinical events at 12 months (TES: 16.1% vs. BMS:
19.5%, p=non-significant) [106].
5.1.3.4. The Genous Bioengineered R Stent and Combo SES. The
Genous Bioengineered R stent (OrbusNeich, FL, US) consists of a
316L stainless steel R Stent BMS (OrbusNeich) which is coated on
its luminal surface with monoclonal, anti-human CD34 antibod-
ies. These antibodies attract circulating endothelial progenitor cells
(EPCs)whichpromote the establishmentof a functional endothelial
layer upon the stent surface and reduce the risk of restenosis and
late stent thrombosis. One possible drawback with this technology
is that the CD34+ markers used to phenotype EPCs are non-specific
and may also sequester unwanted cells including smooth mus-
cle progenitor cells that can contribute to neointimal proliferation
[107]. To date, the Genous stent has been evaluated in a number
of prospective registries and clinical trials such as HEALING FIM,
HEALING II, GENIUS-STEMI and TRIAS.
HEALING FIM is a prospective registry involving 16 patients
that demonstrated the safety and feasibility of the Genous Bio-
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Fig. 4. Optical microscipy images of Janus TES (Sorin Biomedica) (a) marginal section with radiopaque marker shown pre-dissolition, (b) marginal section with radiopaque
marker shown post-dissolution and (c) medial section pre-dissolition and (d) medial section pre-dissolition.
engineered R stent in low-risk patients with modest rates of mean
late lumen loss (0.63±0.52 mm) and low rates of adverse clini-
cal events (6.3%) observed at 6 and 9 months, respectively [108].
The HEALING II study is a second prospective registry involving 63
patients that further demonstrated the feasibility of the Genous
Bioengineered R stent. Initially, at 6 months, in-stent late loss was
reported as 0.78±0.39mm, however, at 18 months a significant
late regression of neointimal hyperplasia was observed with in-
stent late loss reported as 0.59±0.31mm (a 16.9% reduction by
matched serial analysis) [109]. It was noted by investigators that
a relative increase in circulating EPC titers at long-term follow-
up correlated with neointimal compaction in individual patients
suggesting an EPC-mediated vascular repair response.
The GENIUS-STEMI trial is a randomised trial involving 100
patients suffering from ST-elevated myocardial ischemia which
was designed to compare the safety and efficacy of the Genous
Bioengineered R stent with cobalt chromium BMSs (Driver BMS
or Coroflex Blue BMS) in terms of adverse clinical events at 6
months. At follow-up, however, increased rates of adverse clinical
events (Genous: 24% vs. BMS: 10%, p=0.03) and stent thrombo-
sis (Genous: 6% vs. BMS: 0%, p=non-significant) were observed
in patients treated with the Genous Bioengineered R stent, and
larger clinical studies were recommended [110]. The TRIAS trial
is a randomised trial involving 193 patients suffering from high
risk de novo lesions that was designed to compare the safety
and efficacy of the Genous Bioengineered R stent with the Taxus
Liberté PES in terms of target-vessel failure at 12months. At follow-
up, a non-significant increase in the rate of target-vessel failure
was observed in patients in the Genous group (Genous: 17.3% vs.
PES: 10.5%, risk difference =6.8%), and was attributed to a higher
incidence of repeat revascularisation. Additionally, 8 month angio-
graphic follow-up revealed significantly higher mean late loss in
patients in the Genous group (Genous: 1.14±0.64mm vs. PES:
0.55±0.61mm, p<0.0001). In contrast, no stent thrombosis was
observed in patients treatedwith theGenous BioengineeredR stent
compared to four stent thromboses in the Taxus Liberté PES group,
despite a significantly lower percentage of patients in the Genous
group undergoing dual anti-platelet therapy [111].
Following the results of these trials, OrbusNeich have developed
the Combo SES, a 316L stainless steel R stent which is coated on
its luminal side with an EPC-capture matrix and is coated on its
abluminal side in a formulation of sirolimus and a biodegradable
polymer. To date, the Combos SES has shown improved endothe-
lialisation andneointimal proliferation compared to theCypher SES
in porcine arteries. Clinical evaluation of the ComboSES is currently
underway in the REMEDEE trial, a randomised trial involving 180
patients that is designed to compare the safety and efficacy of the
Combo SES with the Taxus Liberté PES in terms of late loss at 9
months [112].
5.2. Bioabsorbable DESs
5.2.1. Bioabsorbable polymer-coated DESs
5.2.1.1. The BVS EES. The BVS EES (Abbott Vascular) is manufac-
tured from PLLA polymer and is coated with a formulation of
everolimus in a poly-d,l-lactide (PDLLA) polymer matrix which
contains and controls the release of everolimus from the stent. As
with the bioabsorbable polymer coatings already discussed, PLLA
and PDLLA polymers are slowly degraded by hydrolysis of ester
links with all by-products metabolised via the Krebs cycle. The
mechanical properties of the PLLA BVS EES appear favourable, with
relativelyhigh levels of radial strength and low levels of stent recoil.
The drug-polymer coating is applied to the entire stent surfacewith
a standard concentrationof approximately 8.2gof everolimusper
mm stent length and is designed to release approximately 80% of
the total dose within 30 days of stent placement. Polymeric strut
absorption is by bulk erosion with full absorption taking approxi-
mately two years.
The revision one BVS EES features circumferential hoops which
are linked by straight bridging segments and have a strut thick-
ness of 0.15mm (Fig. 5). The safety and feasibility of the revision
one BVS EES was evaluated in the first cohort of the ABSORB trial,
a non-randomised trial involving 30 patients suffering from low-
risk de novo lesions. Procedural and device success were 100% and
94%, respectively, with very low rates of adverse clinical events
observed at one (3.3%), two (3.4%) and three years (3.4%) and com-
plete freedom from stent thrombosis at three years [113–115]. In
November 2009, investigators announced complete enrolment in
a second cohort in the ABSORB trial that is designed to assess the
safety and efficacy of a revised BVS EES.
The revision two BVS EES is constructed from the same poly-
mermaterial (PLLA) as the revision one BVS EES, however, different
processing techniques have been adopted to increase the dura-
tion of radial support, while maintaining the same total period of
absorption (approximately two years). Although the strut thick-
ness is unchanged (0.15mm), the revision two BVS EES features
a redesigned strut configuration, similar to that of the Multi-Link
BMS, which ensures improved vessel support and uniform drug-
delivery. The revision two BVS EES is currently under evaluation in
the second cohort of the ABSORB trial, a randomised trial involv-
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Fig. 5. (a) Revision one BVS EES geometry and (b) Magnification of revision two BVS EES with radiopaque markers shown.
ing 101 patients which has demonstrated the safety and feasibility
of the revision two BVS EES in terms of mean late loss at 6 months
(0.19mm) [116]. Further clinical evaluation of the BVS EES is sched-
uled in the ABSORB EXTEND trialwhich is set to enrol 1000 patients
and is designed to assess the safety and efficacy of the revision two
BVS EES in more complex patients and lesions.
5.2.1.2. The BTI ideal SES. The BTI SES (Bioabsorbable Therapeutic
Inc., CA, US) consists of a stent platform which is manufactured
from polylactide anhydride (PA) and salicylic acid and is coated
with a formulation of sirolimus in a bioabsorbable polymer matrix
which is derived from salicylic and adipic acids. This novel stent is
designed to release both sirolimus and salicylic acid to the arterial
wall. Salicylic acid, the active ingredient in aspirin, has well-known
anti-inflammatory properties as well as anti-platelet effects. As
with the bioabsorbable polymers already discussed, degradation
is by hydrolysis of ester bonds with all by-products metabolised
via the Krebs cycle. The drug-polymer coating is applied to the
abluminal stent surface with a standard concentration of approxi-
mately 8.3g of sirolimus per mm stent length and is designed to
release the entire drug dose over 1 month. Polymeric strut absorp-
tion is by surface erosionwith full absorption taking approximately
6–12 months. During absorption of the stent approximately 10g
of salicylic acid is released to the arterial wall.
The BTI SES was first evaluated in the WHISPER trial, a first-in-
man trial involving 11 patients, during which the BTI SES exhibited
acceptable safety and structural integrity without incurring any
acute or chronic recoil. Due to insufficient neointimal suppres-
sion which was attributed to insufficient drug dosing and rapid
drug release, however, the design of the BTI SES has been revised.
The revised BTI SES possesses thinner struts (0.175 vs. 0.20mm),
a higher dose of sirolimus, a slower drug-release profile, a lower
crossing profile and lower percent stent-to-artery wall coverage
(57%vs. 65%). Evaluationof the revisedBVSSES is currently ongoing
[117].
5.2.2. Polymer-free DESs
5.2.2.1. The REVA stent. The REVA stent (REVA Medical, CA, US)
consists of a bioabsorbable stent platform manufactured from
monomeric units of L-tyrosine which is impregnated with iodine
molecules for radiopacity. This bioabsorbable stent has a period of
absorption of approximately three years, can act as a drug-delivery
matrix with a tuneable absorption rate and features a unique
slide-and-lock design that permits expansion without material
deformation. The REVA stent was first evaluated in the RESORB
trial, a first-in-man trial involving 27 patients, during which the
REVA stent successfully dilated lesions at implant, achieving good
acute gain and reduction in diameter stenosis with no evidence
of shrinkage or negative remodelling observed post-deployment
[118].
At 6 and 12 month follow-up, however, higher than anticipated
rates of target-lesion revascularisation (6 month: 60%, 12 month:
67%), driven by the inability of the tyrosine-derived polymer to
resist clinical loading, were reported and neointimal hyperplasia at
6months (18.0±0.91mm)was found to be similar to that observed
with BMSs [119]. Following the results of the RESORB trial the
REVA stent underwent a redesign which led to the development
of the ReZolve SES (REVA Medical). The ReZolve SES features an
improved spiral slide-and-lock design, incorporates a more robust
polymer which has been modified to meet clinical demands and
facilitates elution of sirolimus. Clinical evaluation of the ReZolve
SES is anticipated [119].
5.2.2.2. The AMS stent. The AMS stent (Biotronik, Berlin, Germany)
consists of a bioabsorbable WE43 magnesium-alloy stent that
possesses both biocompatible and bio-corrosive properties while
maintaining strength similar to that of 316L stainless steel (Fig. 6).
The AMS stent was first evaluated in the PROGRESS-AMS trial,
a non-randomised trial involving 63 patients suffering from de
novo lesions that demonstrated the safety and feasibility of a
drug-free AMS with zero death, stent thrombosis or myocardial
infarction observed at 12 months. Disappointingly, however, high
rates of overall target-lesion revascularisation were observed at
four (39.7%) and 12 months (45.0%) [120]. This high rate of target-
lesion revascularisation was attributed to the rate of absorption
of the device with a lack of radial support allowing for excessive
negative remodelling. Modification of the mechanical properties
of the AMS stent for prolonged degradation and drug-delivery are
currently underway.
6. Discussion
To date, a number of studies have confirmed the long-term
safety and efficacy of DESs compared to BMSs. Results from long-
term follow-up of the pivotal SIRIUS, TAXUS IV, ENDEAVOR II and
SPIRIT FIRST trials have shown no evidence of disproportionate
late clinical events with DESs compared to BMSs [22,121–123]. In
a recent meta analysis involving 18023 patients DESs and BMSs
were associated with similar rates of cardiac mortality at up to four
years with a marked reduction in rates of target-lesion revascular-
isation reported in patients treated with DESs (SES vs. BMS, hazard
ratio =0.30 and PES vs. BMS, hazard ratio =0.42) [72]. A separate
meta-analysis involving a total of 192371patients has also reported
no significant differences in long-term mortality rates after DES or
BMS use in both on-label (DES vs. BMS: hazard ratio =0.97, p=0.72)
and off-label (DES vs. BMS: hazard ratio =0.84, p=0.24) indications.
Furthermore, marked reduction in taget-lesion revascularisation
was observed with DES use in both randomised controlled trials
(DES vs. BMS: hazard ratio =0.45, p<0.001) and observational stud-
ies (DES vs. BMS: hazard ratio =0.54, p<0.001) compared to BMSs
[73].
Being the first DESs to receive both CE and FDA approval, the
first-generation Cypher SES and Taxus Express2 PES have been sub-
ject to a large number of investigational and comparative trials. In
a randomised trial carried out to compare the safety and efficacy
of the Cypher SES with the Taxus Express2 PES, fewer adverse clin-
ical events were reported in the Cypher SES group at 9 months
(SES: 6.2% vs. PES:10.8%, p=0.009). This difference was attributed
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Fig. 6. AMS stent (Biotronik) (A) post-expansion, (B) pre-expansion and (C) electron microscopy magnification.
to a lower incidence of taarget-leison revascularisation (SES: 4.8%
vs. PES: 8.3%, p=0.03) and angiographic in-segment restenosis
(SES: 6.6% vs. PES: 11.7%, p=0.02) [55]. In a meta-analysis of 16
randomised trials, involving 8695 patients, the Cypher SES was
identifiedwith similar rates of cardiac death andmyocardial infarc-
tion but significantly reduced rates of reintervention (hazard ratio:
0.74, p<0.001) and stent thrombosis (hazard ratio: 0.66, p=0.02)
compared to the Taxus Express2 PES across a number of patient and
lesion subgroups at two years [124]. Although an exact cause for
these findings is yet to be identified, investigators have suggested
pharmacological differences between the two drugs, differences in
dose response among high risk patient and lesion subgroups, and
differences in release kinetics and polymer coatings employed by
the two DESs as possible causes.
The Cypher SES has also compared favourably with second-
generation DESs based on the findings of two recent trials,
SORT-OUT-III and ZEST. The SORT-OUT-III trial is a randomised,
all-comers trial involving 2773 patients that demonstrated the
superiority of the Cypher SES over the Endeavor ZES in terms of
adverse clinical events at nine (ZES: 6% vs. SES: 3%, p=0.0002) and
18 months (ZES: 10% vs. SES: 5%, p<0.0001) [46]. The ZEST trial
is a randomised, all-comers trial involving 2640 patients which
has identified the Cypher SES with improved rates of adverse clin-
ical events compared to both the Taxus Liberté PES and Endeavor
ZES at 12 months (SES: 8.3% vs. ZES: 10.1% vs. PES: 14.2%, p=0.25
and p<0.001, respectively) [125]. In the recent COMPARE trial, a
randomised trial involving 1800 patients, the Xience-V EES was
identified with superior rates of adverse clinical events compared
to the Taxus Liberté PES at 12 months (EES: 6% vs. PES: 9%, p=0.02)
[38]. The performance of the Xience-V EES relative to the Cypher
SES is to be evaluated in the EXCELLENT trial, a randomised trial
due to enrol approximately 1800 patients to assess the efficacy of
the Xience-V EES against the Cypher SES in terms of lumen loss and
target-vessel failure at 9 months.
It is worth noting that the results of many of the clinical trials
reported thus far have been interpreted based on the assump-
tion that endpoints such as late loss are directly indicative of the
long term performance of DESs. In recent years, the significance of
endpoints such as late loss and target-lesion revascularistion have
been called into question, particularly following thepresentation of
long-term follow-upof theENDEAVOR III andSIRTAX trials. Though
the Cypher SES was associated with significantly less in-segment
late loss at 8 months (ZES: 0.34±0.44mm vs. SES: 0.13±0.32mm,
p<0.001) and lower incidence of target lesion-revascularisation at
9 months (ZES: 9.8% vs. SES: 3.5%, p=0.04) in the ENDEAVOR III
trial, the absolute difference in rates of target-lesion revascularisa-
tionatfiveyearswas reduced to just 1.6% [19,21] Thisphenomenon,
knownas late catch-up,wasalso reportedat long-term follow-upof
the SIRTAX trial, a comparative study involving the Cypher SES and
theTaxusExpress2 PES, inwhichangiographic in-stent late losswas
significantly lower in patients treated with the Cypher SES arm at 8
months (SES: 0.12±0.36mmvs. PES: 0.25±0.49mm,p<0.001)but
comparable between both arms at five years (SES: 0.30±0.51mm
vs. PES: 0.37±0.51mm, p<0.21) [55]. Further comparison of the
Endeavor ZES and the Cypher SES is currently underway in the
PROTECT trial, a randomised trial involving 8800 patients which
completed enrolment in December 2008.
Commenting on the results of these trials investigators have
noted that neointimal formation may follow different timelines
with different DESs. It has been speculated that late catch-up
may have little to do with the different stent platforms and drugs
employed by the DESs but is more likely linked to the long-term
biological effect of the polymer coatings that they employ. It has
also been suggested that long-term data from comparative clinical
trials such as the ENDEAVOR III and SIRTAX trials, in which sig-
nificant differences in DES performance emerge long after primary
endpoints have been assessed, may redefine how clinical trials of
DESs are designed and conducted. The long-term results of current
and future comparative DES trials are eagerly anticipated.
In terms of medical engineering, DESs have benefitted consid-
erably from numerous avenues of research over the past decade.
Identification and implementation of high strength biologically
inert materials has facilitated the design of DESs with signifi-
cantly reduced stent struts, improving overall device safety and
deliverability. The development of bioabsorbable materials should
further improve the long-term safety of stent platforms and coat-
ings with numerous devices currently showing promise in clinical
trials. Innovations in micro-fabrication have led to the emergence
ofnoveldrug-deliverymechanismssuchasmicroporous-basedand
reservoir-baseddrug-delivery,whilemedical imaging technologies
and numerical methods such as finite element analysis and com-
putational fluid dynamics have emerged as powerful tools in the
design and optimisation of DESs [126–129].
The introduction and development of DESs over the past decade
has revolutionised the treatment of CAD with reported reductions
in rates of ISR of between 60-80% compared to BMSs. As with most
newmedical devices, however, first-generationDESs suffered from
a number of defects. Many of these defects have been addressed
with the second-generation of DESs and today, research is centred
on further improving the overall efficacy and long-term safety of
DESs. With the annual international market for DESs swelling to
over D5 billion and with dozens of companies currently develop-
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ing innovative stent platforms, potent anti-restenotic coatings and
novel drug-deliverymechanisms it is possible that anoptimumDES
for the treatment of CAD will emerge in the coming years.
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